Article
Urology & Nephrology
Steven Fishbane, Carol A. Pollock, Mohamed El-Shahawy, Elizabeth T. Escudero, Anjay Rastogi, Bui Pham Van, Lars Frison, Mark Houser, Maksym Pola, Dustin J. Little, Nicolas Guzman, Pablo E. Pergola
Summary: Roxadustat effectively increases hemoglobin in patients with dialysis-dependent CKD, and its adverse event profile is comparable to that of epoetin alfa.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2022)
Article
Medicine, General & Internal
Ping Zhang, Yan Jiang, Chunping Xu, Linghui Zhou, Hongguang Zheng, Deqiong Xie, Minghao Guo, Xiangyang Huang, Guoyuan Lu, Hongli Jiang, Hongyu Qiu, Bicheng Liu, Shaomei Li, Qinkai Chen, Yu'ou Xia, Bengui Sun, Xiao Yang, Shiying Zhang, Shutong Du, Mindan Sun, Menghua Chen, Aimin Zhong, Xiaoling Wang, Zhanzheng Zhao, Hua Zhou, Guisen Li, Yueqin Ren, Qun Luo, Aicheng Yang, Ping Luo, Shuifu Tang, Chengyun Xu, Qin Wang, Xiaoxia Wang, Tiekun Yan, Wei He, Shuguang Qin, Weili Zhang, Lu Lv, Cheng Wang, Hong Liu, Jing Li, Qiong Wu, Chao Pan, Chuan Li, Liangliang He, Jianghua Chen
Summary: The study compared the efficacy and safety of pegmolesatide and epoetin alfa in treating anemia in Chinese dialysis patients. The results showed that monthly subcutaneously injection of pegmolesatide was as effective and safe as conventional epoetin alfa administration one to three times a week in treating anemia.
Article
Urology & Nephrology
Bhanu Prasad, Meric Osman, Maryam Jafari, Lexis Gordon, Navdeep Tangri, Thomas W. Ferguson, Shan Jin, Joanne Kappel, Diane Kozakewycz
Summary: The study found significant differences in healthcare utilization between high-risk and low-risk groups of CKD patients, with higher costs for hospital admissions, physician visits, and prescription drugs in the high-risk group.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2022)
Article
Oncology
Kamel Laribi, Dominique Spaeth, Florian Scotte, Isabelle Ray-Coquard
Summary: The study evaluated the effectiveness and safety of a biosimilar of epoetin alfa in chemotherapy-induced anemia, as well as the impact of iron supplementation. Results showed that the biosimilar was effective and well tolerated for treating chemotherapy-induced anemia. However, the rate of patients receiving iron supplementation through the intravenous route was insufficient.
Article
Urology & Nephrology
Caitlyn Vlasschaert, Amy J. M. McNaughton, Michael Chong, Elina K. Cook, Wilma Hopman, Bryan Kestenbaum, Cassianne Robinson-Cohen, Jocelyn Garland, Sarah M. Moran, Guillaume Pare, Catherine M. Clase, Mila Tang, Adeera Levin, Rachel Holden, Michael J. Rauh, Matthew B. Lanktree
Summary: This study found that genetic mutations in hematopoietic stem cells are associated with the progression of chronic kidney disease and anemia, and individuals with these mutations have a higher risk of kidney failure.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2022)
Article
Medicine, Research & Experimental
Jonathan Barratt, Wladyslaw Sulowicz, Michael Schomig, Ciro Esposito, Michael Reusch, James Young, Botond Csiky
Summary: This integrated phase 3 analysis evaluated the efficacy and cardiovascular safety of roxadustat compared to ESA in dialysis-dependent patients with anemia of CKD. Results showed non-inferiority of roxadustat to ESA in terms of hemoglobin change and risks for cardiovascular events, with consistent safety profiles between the two treatment groups. Roxadustat represents a promising oral alternative to ESA for managing anemia of CKD in dialysis-dependent patients.
ADVANCES IN THERAPY
(2021)
Article
Pharmacology & Pharmacy
Guillermo di Girolamo, Guillermo A. A. Keller, Lara Beider, Claudio D. D. Gonzalez, Maria F. Gonzalez Bagnes, Eliseo Gonzalez, M. Cecilia Fornari, Roberto A. A. Diez
Summary: Hemax (R) is a recombinant human epoetin alfa product developed in Argentina, initially as a lyophilized powder and more recently as a prefilled syringe. In a clinical trial with healthy volunteers, Hemax (R) was found to be bioequivalent to the innovator product Eprex (R) in terms of pharmacokinetic profile. The study demonstrated similar absorption velocity, extent, and elimination for both formulations.
FUNDAMENTAL & CLINICAL PHARMACOLOGY
(2023)
Article
Endocrinology & Metabolism
Joao Victor Salgado, Miguel Angelo Goes, Natalino Salgado Filho
Summary: The global nephrology community acknowledges the increasing burden of kidney disease and emphasizes on early diagnosis, understanding of disease progression, and development of new therapeutic interventions. FGF21 is considered a key regulator of lipid, glucose, and energy metabolism, as well as stress responses. While promising results have been shown with FGF21 analogs in metabolic disease, its exact role in kidney function remains poorly understood.
METABOLISM-CLINICAL AND EXPERIMENTAL
(2021)
Article
Medicine, Research & Experimental
Jonathan Barratt, Frank Dellanna, Jose Portoles, Gabriel Choukroun, Luca De Nicola, James Young, Nada Dimkovic, Michael Reusch
Summary: This study aimed to investigate the safety of roxadustat compared with erythropoiesis-stimulating agents (ESA) in non-dialysis-dependent (NDD) or incident dialysis-dependent (ID-DD) chronic kidney disease (CKD) patients with anemia. The results showed that roxadustat was comparable to ESA in terms of major adverse cardiovascular events (MACE), all-cause mortality, and treatment-emergent adverse events (TEAEs). There was no evidence of increased risk of cardiovascular events or mortality with roxadustat.
ADVANCES IN THERAPY
(2023)
Review
Urology & Nephrology
Qiaoqiao Zhou, Mian Mao, Jing Li, Furong Deng
Summary: This meta-analysis evaluates the efficacy and safety of roxadustat for anemia in dialysis-dependent chronic kidney disease patients. The results show that roxadustat significantly increases hemoglobin levels and improves iron utilization. It also decreases low-density lipoprotein-cholesterol and total cholesterol. There were no significant differences in treatment-emergent adverse events, treatment-emergent serious adverse events, and major adverse cardiovascular events between roxadustat and erythropoiesis-stimulating agents.
Article
Veterinary Sciences
Fabiola De Oliveira Paes-Leme, Eliana M. Souza, Paulo Ricardo Oliveira Paes, Maderleine Geisa Gomes, Felipe Santos Muniz, Marco Tulio Gomes Campos, Renata Barbosa Peixoto, Patricia Donado Vaz de Melo, Marcio H. L. Arndt, Adriane Costa Val
Summary: In critically ill dogs in the ICU, Cystatin C can be used as a reliable biomarker for early diagnosis of acute kidney injury.
FRONTIERS IN VETERINARY SCIENCE
(2021)
Article
Pharmacology & Pharmacy
Eric Linn, Heather Morrison, Michael Sanchez, Theodore Heierman
Summary: This study examined the effectiveness of pharmacy consultation in managing dosing of epoetin alfa-epbx for inpatients on hemodialysis. The results showed that pharmacist-driven dosing led to significant reductions in acquisition cost and average total dose per patient.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
(2023)
Article
Medicine, General & Internal
Zhaoli Gao, Yingying Hu, Yanxia Gao, Xiaotian Ma, Zhao Hu
Summary: This study investigated the association between hepcidin, RET-He, and anemia-related indicators in chronic kidney disease (CKD). Hepcidin was found to be positively associated with IL-6 and negatively associated with total iron binding capacity, intrinsic factor antibody, and transferrin. RET-He was positively associated with Hb, serum ferritin, serum iron, transferrin saturation, and negatively associated with serum creatinine, reticulocyte, IL-6, and STfR. Hepcidin had no effect on RET-He, while IL-6 was independently associated with hepcidin and RET-He, suggesting a threshold for IL-6 stimulation of hepcidin-25 expression for indirect regulation of RET-He.
Review
Medicine, General & Internal
Hanna Cholerzynska, Wiktoria Zasada, Hanna Michalak, Milosz Miedziaszczyk, Andrzej Oko, Ilona Idasiak-Piechocka
Summary: Acute kidney injury (AKI) and sudden exacerbation of chronic kidney disease (CKD) often require urgent kidney replacement therapy (UKRT). Peritoneal dialysis (PD) is seen as a viable option for managing these patients. This review examines recent literature on the clinical outcomes of urgent-start peritoneal dialysis (USPD) in CKD and AKI.
JOURNAL OF CLINICAL MEDICINE
(2023)
Review
Medicine, General & Internal
Jie Liu, Fan Yang, Yousuf Waheed, Shulin Li, Kun Liu, Xinglei Zhou
Summary: The incidence of chronic kidney disease (CKD) is increasing worldwide, with a current prevalence rate of 13.4%. In China, there are over 120 million CKD patients and this number is expected to rise. Decreased synthesis of erythropoietin (EPO) is a common abnormality in CKD patients, leading to anemia and affecting iron metabolism. Anemia is a major complication in CKD patients, with multiple causes such as platelet dysfunction, iron deficiency, and shortened red blood cell life. Roxadustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, has shown therapeutic effects in CKD by regulating iron metabolism and promoting erythropoiesis. It has advantages over EPO in clinical experiments. This review summarizes the mechanisms, clinical applications, effectiveness, and safety of roxadustat.
KOREAN JOURNAL OF INTERNAL MEDICINE
(2023)
Editorial Material
Medicine, General & Internal
Catherine M. Clase, Edouard L. Fu, Meera Joseph, Rupert C. L. Beale, Myrna B. Dolovich, Meg Jardine, Johannes F. E. Mann, Roberto Pecoits-Filho, Wolfgang C. Winkelmayer, Juan J. Carrero
ANNALS OF INTERNAL MEDICINE
(2020)
Article
Urology & Nephrology
Juliana Leme, Murilo Guedes, John Larkin, Maggie Han, Ana Beatriz Lesqueves Barra, Maria Eugenia F. Canziani, Americo Lourenco Cuvello Neto, Carlos Eduardo Poli-de-Figueiredo, Thyago Proenca de Moraes, Roberto Pecoits-Filho
Article
Urology & Nephrology
Roberto Pecoits-Filho, Glen James, Juan Jesus Carrero, Eric Wittbrodt, Steven Fishbane, Alyshah Abdul Sultan, Hiddo J. L. Heerspink, Katarina Hedman, Eiichiro Kanda, Hungta (Tony) Chen, Naoki Kashihara, James Sloand, Mikhail Kosiborod, Supriya Kumar, Mitja Lainscak, Matthew Arnold, Carolyn S. P. Lam, Bjorn Holmqvist, Carol Pollock, Peter Fenici, Peter Stenvinkel, Jennie Medin, David C. Wheeler
Summary: The DISCOVER CKD program aims to provide contemporary real-world insight into clinical management, quality of life, treatment patterns, and dietary habits of patients with chronic kidney disease, with the goal of improving their management and prognosis by understanding the challenges and consequences they face.
CLINICAL KIDNEY JOURNAL
(2021)
Article
Medicine, General & Internal
Charles R. Tomson, Alfred K. Cheung, Johannes F. E. Mann, Tara Chang, William C. Cushman, Susan L. Furth, Fan Fan Hou, Gregory A. Knoll, Paul Muntner, Roberto Pecoits-Filho, Sheldon W. Tobe, Lyubov Lytvyn, Jonathan C. Craig, David J. Tunnicliffe, Martin Howell, Marcello Tonelli, Michael Cheung, Amy Earley, Joachim H. Ix, Mark J. Sarnak
Summary: This article presents key information on the KDIGO 2021 clinical practice guideline for managing high blood pressure in patients with chronic kidney disease, including new evidence, methods, and recommendations. The guideline aims to support shared decision making by healthcare professionals worldwide, with 11 recommendations and 20 practice points, focusing on standardized blood pressure measurement and a target systolic blood pressure of less than 120 mm Hg.
ANNALS OF INTERNAL MEDICINE
(2021)
Review
Medicine, General & Internal
Murilo Guedes, Roberto Pecoits-Filho
Summary: Diabetic kidney disease (DKD) is a major cause of chronic kidney disease (CKD) worldwide, placing a significant burden on patient outcomes. Recent interventions and guidelines emphasize multidimensional approaches for optimal clinical management. Challenges lie in implementing these approaches to improve clinical outcomes and address residual risk in DKD.
JOURNAL OF INTERNAL MEDICINE
(2022)
Letter
Urology & Nephrology
Murilo Guedes, Bruce Robinson, Brian Bieber, Roberto Pecoits-Filho
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2022)
Review
Urology & Nephrology
Toby Humphrey, Mogamat Razeen Davids, Mogamat-Yazied Chothia, Roberto Pecoits-Filho, Carol Pollock, Glen James
Summary: This study provides a comprehensive overview of the epidemiology of hyperkalaemia, including its prevalence and incidence in different populations, healthcare settings, and continents. The prevalence of hyperkalaemia in adults is 6.3%, with an incidence of 2.8 cases per 100 person years. In the general population, the prevalence is 1.3%, with an incidence of 0.4 cases per 100 person years. Prevalence varies by sex and the definition/threshold used. Patients with end-stage kidney disease, kidney transplant patients, and patients with acute kidney injury have the highest prevalence of hyperkalaemia.
CLINICAL KIDNEY JOURNAL
(2022)
Editorial Material
Urology & Nephrology
Murilo Guedes, Roberto Pecoits-Filho
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2022)
Review
Urology & Nephrology
Murilo Guedes, Robin W. M. Vernooij, Andrew Davenport, Martin K. Kuhlmann, Fabienne Aregger, Roberto Pecoits-Filho
Summary: This article reviews the practical aspects of implementing HDF and discusses its impact on various biochemical, patient-reported, and clinical outcomes. It emphasizes the delivery of high-volume HDF therapy and its effects on solute clearance, inflammation, hemodynamic stability, cardiac outcomes, nutrition, quality of life, morbidity, and mortality.
SEMINARS IN DIALYSIS
(2022)
Article
Urology & Nephrology
Glen James, Juan Jose Garcia Sanchez, Juan Jesus Carrero, Supriya Kumar, Roberto Pecoits-Filho, Hiddo J. L. Heerspink, Stephen Nolan, Carolyn S. P. Lam, Hungta Chen, Eiichiro Kanda, Naoki Kashihara, Matthew Arnold, Mikhail N. Kosiborod, Mitja Lainscak, Carol Pollock, David C. Wheeler
Summary: According to the KDIGO classification, as urinary albumin increases, the prevalence of heart failure, hypertension, and type 2 diabetes increases; with declining baseline eGFR, the incidence of mortality and adverse cardiovascular and renal outcomes increases.
KIDNEY INTERNATIONAL REPORTS
(2022)
Article
Medicine, Research & Experimental
Bartholomeus J. A. Willigers, Mario Ouwens, Andrew Briggs, Hiddo J. L. Heerspink, Carol Pollock, Roberto Pecoits-Filho, Navdeep Tangri, Csaba P. P. Kovesdy, David C. C. Wheeler, Juan Jose Garcia Sanchez
Summary: To minimize uncertainty in projecting long-term outcomes in clinical trials, researchers developed a novel method that incorporates expert opinion in a Bayesian analysis. The results showed that using expert opinion in Bayesian analysis produced a smaller range of survival values compared to frequentist methods.
ADVANCES IN THERAPY
(2023)
Article
Urology & Nephrology
Murilo Guedes, Junhui Zhao, Brian LaMoreaux, Brad Marder, Barry Gorlitsky, Vinicius Domingues, Matthew B. Rivara, Susie Lew, Bruce Robinson, Roberto Pecoits-Filho, Angelo Karaboyas, Ali Alaradi, Pieter Evenepoel, Michel Jadoul, Manish Sood, Rita Suri, Xiaonong Chen, Yuqing Chen, Fanfan Hou, Xinling Liang, Zhaohui Ni, Li Zuo, Christian Combe, Fitsum Guebre-Egziabher, Pablo Antonio Urena Torres, Werner Kleophas, Elke Schaeffner, Thomas Weinreich, Giuliano Brunori, Loreto Gesualdo, Francesco Locatelli, Masafumi Fukagawa, Masaaki Inaba, Masaomi Nangaku, Kosaku Nitta, Kazuhiko Tsuruya, Saeed Al-Ghamdi, Mohammed Al Ghonaim, Fayez Hejaili, Ayman Karkar, Faissal Shaheen, Jamal Al Wakeel, Naser Alkandari, Anas Alyousef, Bassam Al Helal, Issa Alsalmi, Yacoub Al Maimani, Fadwa Al Ali, Abdulla Hamad, Aleix Cases, Almudena Vega Martinez, Patricia de Sequera, Anders Christensson, Stefan Jacobson, Samra Abouchacra, Mohamed Hassan, Ali Abdulkarim Al Obaidli, Mona Al Rukhaimi, Abdul Kareem Saleh, Elham Asgari, Indranil Dasgupta, Hugh Rayner, David Johnson, Jeffrey Perl, Mauricio Sanabria, Hideki Kawanishi, Yong-Lim Kim, Talerngsak Kanjanabuch, Simon Davies, Ronald Pisoni, Bruce Robinson, Jenny Shen
Summary: The prevalence of gout is high in patients with kidney disease and its association with outcomes in hemodialysis and peritoneal dialysis populations in North America is unknown.
Article
Urology & Nephrology
Cesar Truyts, Melani Custodio, Roberto Pecoit-Filho, Thyago Proenca de Moraes, Vanda Jorgetti
Summary: This study showed a significant association between high phosphorus serum levels and low parathyroid hormone levels with cardiovascular mortality in peritoneal dialysis patients, according to KDOQI and KDIGO guidelines.
JORNAL BRASILEIRO DE NEFROLOGIA
(2021)
Article
Urology & Nephrology
Rafael Weissheimer, Sergio Gardano Elias Bucharles, Cesar Augusto Madid Truyts, Vanda Jorgetti, Ana Elizabeth Figueiredo, Pasqual Barrett, Marcia Olandoski, Roberto Pecoits-Filho, Thyago Proenca de Moraes
Summary: The study aimed to describe the prevalence of CKDMBD biomarkers in a large cohort of PD patients in Brazil. The findings showed a significant presence of biochemical disorders related to CKD-MBD in this dialysis population.
JORNAL BRASILEIRO DE NEFROLOGIA
(2021)
Article
Transplantation
Roberto Pecoits-Filho, John Larkin, Carlos Eduardo Poli-de-Figueiredo, Americo Lourenco Cuvello-Neto, Ana Beatriz Lesqueves Barra, Priscila Bezerra Goncalves, Shimul Sheth, Murilo Guedes, Maggie Han, Viviane Calice-Silva, Manuel Carlos Martins de Castro, Peter Kotanko, Thyago Proenca de Moraes, Jochen G. Raimann, Maria Eugenia F. Canziani
Summary: In this study, the effects of high-volume online hemodiafiltration (HDF) on physical activity (PA) in dialysis patients were investigated. Despite achieving a high convective volume and positive impact on solute removal, HDF did not have a statistically significant treatment effect on PA compared to high-flux hemodialysis (HD). However, there were modest treatment effects observed, particularly in the hours following dialysis, which may warrant further investigation into the clinical significance.
NEPHROLOGY DIALYSIS TRANSPLANTATION
(2021)